PSNL
HealthcarePersonalis, Inc. · Medical - Diagnostics & Research · $760M
What is Personalis, Inc.?
Personalis, Inc. is a cancer genomics company focused on advanced sequencing and data analysis to support cancer therapy development and large-scale genetic research. Headquartered in Menlo Park, California, it serves biopharma companies, universities, nonprofits, and government entities worldwide.
Personalis generates revenue by providing genomic sequencing services and data analysis platforms to customers developing cancer therapies and conducting genetic research. Its technology profiles tumors and their immune environments from tissue or plasma samples, enabling biomarker identification, neoantigen prediction, and personalized tumor tracking. The company partners with institutions including Mayo Clinic and Moores Cancer Center to advance clinical and therapeutic applications of its genomic platforms.
Personalis was incorporated in 2011 and is headquartered in Menlo Park, California.
- NeXT Platform — comprehensive tumor and immune microenvironment data analysis
- NeXT Liquid Biopsy — tumor profiling from plasma samples
- NeXT Personal — personalized liquid biopsy for patient tumor tracking
- NeXT Dx Test — genomic cancer profiling enabling composite biomarkers
- ACE Platform — neoantigen prediction and novel drug target selection
Is PSNL a Good Stock to Buy?
UQS Score rates PSNL as Poor overall, reflecting broad weakness across most fundamental pillars.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's near-term financial stability is less concerning than its other fundamentals. This provides some floor for investors monitoring the name.
Quality, Moat, and Growth all register as Weak, pointing to limited competitive differentiation, constrained revenue momentum, and below-average business fundamentals relative to sector peers. Valuation is rated Elevated, meaning the market price does not appear to reflect these underlying challenges.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account at uqs-score.com. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PSNL pay dividends?
No — Personalis, Inc. does not currently pay a dividend.
Personalis does not currently pay a dividend. As an early-stage cancer genomics company, capital is directed toward platform development, clinical partnerships, and expanding its sequencing capabilities rather than returning cash to shareholders. Investors seeking income from this sector should look elsewhere, as reinvestment remains the priority.
When does PSNL report earnings?
Personalis reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's recent results reflect the challenges captured in its Weak Quality and Growth pillar ratings — revenue scale and profitability remain areas of concern relative to sector peers. Progress in biopharma partnerships and platform adoption will be key factors to watch each quarter.
For the most recent quarter's results and guidance, visit Personalis's investor relations page directly.
PSNL Price History
-72.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Personalis, Inc.?
Based on Personalis, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
PSNL Long-term Outlook
The fundamental outlook for PSNL is cautious, shaped by Weak Growth and Weak Quality pillar ratings. Meaningful improvement would likely require accelerating adoption of its NeXT and ACE platforms among biopharma customers and expanding its partnership network beyond current collaborators. The Good Risk rating offers some reassurance around near-term stability, but the Elevated Valuation pillar suggests the current market price may already factor in optimistic scenarios that the underlying fundamentals have yet to support.
Growth drivers
- Expanding biopharma customer adoption of liquid biopsy and tumor profiling platforms
- Deepening institutional partnerships such as Mayo Clinic and Moores Cancer Center
- Growing demand for personalized cancer genomics in clinical and therapeutic research
Key risks
- Weak Moat rating signals limited pricing power and competitive differentiation
- Elevated Valuation leaves little margin of safety if growth disappoints
- Sustained revenue scale challenges in a competitive cancer genomics landscape
PSNL vs Peers
Personalis operates in a competitive cancer diagnostics and genomics space alongside several specialized peers.
Aclaris focuses on dermatology therapeutics rather than oncology genomics, representing a different application of precision medicine.
Fulgent offers a broader genetic testing menu spanning oncology and rare disease, giving it more diversified revenue streams than Personalis.
Castle Biosciences specializes in skin cancer genomic testing with a commercially launched diagnostic portfolio targeting dermatology clinicians.
Frequently Asked Questions
What does Personalis do?
Personalis is a cancer genomics company that provides advanced sequencing and data analysis services. Its platforms profile tumors and immune environments from tissue or plasma, helping biopharma companies, universities, and government entities develop cancer therapies and conduct large-scale genetic research.
Does PSNL pay dividends?
No, Personalis does not pay a dividend. The company reinvests available capital into its genomic platforms and clinical partnerships. Investors focused on dividend income should be aware that no distribution is currently offered.
When does PSNL report earnings?
Personalis reports on a quarterly cadence, as is standard for US-listed companies. For confirmed dates and the most recent results, check the investor relations section of the Personalis website directly.
Is PSNL a good stock to buy?
UQS Score rates PSNL as Poor overall. Quality, Moat, and Growth pillars are all Weak, while Valuation is Elevated — meaning the price does not appear to reflect the underlying fundamental challenges. The full pillar breakdown is available to Pro members on uqs-score.com.
Is PSNL overvalued?
The UQS Valuation pillar for PSNL is rated Elevated, suggesting the current market price may not be well-supported by the company's fundamental profile. Investors should weigh this against the Weak Quality and Growth ratings before drawing conclusions.
How does PSNL compare to its competitors?
Compared to peers like Fulgent Genetics and Castle Biosciences, Personalis has a narrower focus on oncology genomics platforms serving biopharma and research customers. Its Weak Moat rating suggests it faces meaningful competitive pressure in this specialized space.
What is PSNL's market cap bracket?
Personalis is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to large- or mega-cap peers in the healthcare sector.
Who founded Personalis?
Personalis was founded by a team with roots in genomics and precision medicine research. The company was incorporated in 2011. For detailed founding history and leadership background, the company's official website and public filings are the most reliable sources.
Is PSNL a long-term quality investment?
As a long-term quality indicator, PSNL's Poor UQS Score — driven by Weak ratings across Quality, Moat, and Growth — signals that the company has not yet demonstrated the durable fundamentals typically associated with high-conviction long-term holdings. The Risk pillar is the one relative positive. Pro members can view the complete analysis.
What is the main competitive advantage of Personalis?
Personalis's differentiation lies in its comprehensive tumor profiling technology — particularly its ability to analyze both tumor tissue and liquid biopsy samples through a unified platform. However, the UQS Moat pillar rates this advantage as Weak, suggesting it has not yet translated into durable competitive positioning.
What sector does PSNL belong to?
Personalis operates in the Healthcare sector, specifically within cancer genomics and molecular diagnostics. It serves biopharma companies, academic institutions, and government research programs developing next-generation cancer therapies.
Unlock Full PSNL Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare PSNL against sector peers side by side
- ✓See Valuation and Risk signals in full detail
- ✓Get the complete analyst-grade quality assessment
Pro Analysis
PSNL — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 17, 2026 | 19.0 | 0.0 | 19.0 | 18.5 | 70.7 | 0.0 | +1.1 |
| Apr 22, 2026 | 17.9 | 0.0 | 19.0 | 18.5 | 63.1 | 0.0 | -0.9 |
| Apr 2, 2026 | 18.8 | 0.0 | 19.0 | 23.1 | 63.1 | 0.0 | — |
PSNL — Pillar Breakdown
Quality
— 0.0/100 (25%)Personalis, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)Personalis, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 70.7/100 (15%)Personalis, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Personalis, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 19/100 (25%)Personalis, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PSNL.
Score Composition
Financial Data
More Stock Analysis
How is the PSNL UQS Score Calculated?
The UQS (Unified Quality Score) for Personalis, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Personalis, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Personalis, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.